Allianz Asset Management GmbH Boosts Stock Position in Qiagen N.V. $QGEN

Allianz Asset Management GmbH increased its position in Qiagen N.V. (NYSE:QGEN) by 53.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,529,224 shares of the company’s stock after buying an additional 534,527 shares during the quarter. Allianz Asset Management GmbH’s holdings in Qiagen were worth $68,028,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. United Services Automobile Association bought a new position in shares of Qiagen in the first quarter worth approximately $239,000. Truist Financial Corp raised its position in shares of Qiagen by 7.7% during the 2nd quarter. Truist Financial Corp now owns 6,170 shares of the company’s stock valued at $297,000 after purchasing an additional 439 shares during the period. OLD National Bancorp IN purchased a new position in shares of Qiagen during the 2nd quarter valued at $254,000. Vontobel Holding Ltd. bought a new position in Qiagen in the 2nd quarter worth $1,594,000. Finally, US Bancorp DE increased its stake in Qiagen by 16.6% in the 2nd quarter. US Bancorp DE now owns 66,901 shares of the company’s stock worth $3,215,000 after buying an additional 9,544 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.89 to $52.63 in a research note on Thursday, December 11th. Barclays reissued an “overweight” rating and issued a $57.89 price target (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. UBS Group reaffirmed a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Two equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $53.04.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Q4 results: EPS of $0.62 and revenue growth of ~3.6% YoY; the company showed solid margins (net margin ~19.6%) and return on equity (~14.8%), which support the earnings quality. View Press Release
• Positive Sentiment: Product/market expansion: Qiagen showcased QIAsprint Connect — a benchtop high-throughput automation system — at SLAS 2026, signaling entry into higher-volume sample‑processing for research labs (potential long‑term revenue upside). Article Title
• Positive Sentiment: Analyst sentiment: Several media/analyst write‑ups highlighted Qiagen among favored healthcare names, which can provide continued analyst support for the shares. Article Title
• Neutral Sentiment: Street comparisons: Coverage summarizes how key Q4 metrics stack up to Wall Street — results are largely in line with expectations but show only modest year‑over‑year improvement. Article Title
• Negative Sentiment: Guidance miss: Management lowered near‑term expectations — Q1 EPS guidance of ~$0.54 (consensus ~$0.60) and Q1 revenue guidance of ~$487.8M (consensus ~$511.8M); FY‑2026 EPS guide of ~$2.50 vs. consensus ~$2.63, while FY revenue guidance is roughly in line. The below‑consensus EPS and Q1 revenue outlook are the primary reasons the stock is under pressure. View Press Release

Qiagen Price Performance

Shares of Qiagen stock opened at $51.79 on Thursday. The stock has a 50 day moving average of $49.62 and a 200 day moving average of $49.66. Qiagen N.V. has a 12 month low of $39.61 and a 12 month high of $57.81. The firm has a market cap of $10.94 billion, a PE ratio of 26.74, a PEG ratio of 2.49 and a beta of 0.67. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, research analysts expect that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.